Tucson, AZ, August 27, 2016 --(PR.com
)-- NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health for $243,164.00 entitled, “Fibrin Targeted Microbubbles and Ultrasound for Treatment of Endocarditis.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the grant, said, “This project draws upon NuvOx’s expertise in nanotechnology to more effectively treat localized disease, in this case endocarditis, particularly in pediatric patients.” Shelby Kutty, MD, MS, PhD, Associate Professor of Pediatrics and Internal Medicine at University of Nebraska Medical Center, co-principal investigator on the project said, “In endocarditis, an infection of the heart, a vegetation composed of platelets, fibrin and bacteria can form which prevents adequate penetration of antibiotics into the area of infection. In this study, NuvOx is developing microbubbles targeted to fibrin. We will then use ultrasound to break up the microbubbles, which in turn can disrupt the vegetation, and hopefully be able to treat the endocarditis more effectively with antibiotics. If successful, this has potential to save lives and improve outcomes, in both children and adults with endocarditis.”
NuvOx is a clinical stage biopharmaceutical company currently in clinical testing of another nanotechnology product for brain cancer. For further information, please contact John McGonigle at NuvOx Pharma at email@example.com.
Disclaimer: Certain statements in this release may constitute “forward-looking statements.” When used in this release, words like “may,” “will,” “can,” “should,” “expect,” “anticipate,” “believe,” “project,” or “intend” and other similar expressions are intended to identify forward-looking statements. Statements regarding future events and developments and future performance, as well as our expectations, beliefs, plans, or projections, are forward-looking statements which reflect only our predictions, assumptions, and estimates regarding future events and circumstances. Actual events or results may differ as a result of risks and uncertainties facing us. The forward-looking statements are based on current expectations as of the date of these statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of future events, new information, or otherwise.